A new analysis indicates that generic versions of semaglutide, the active ingredient in Wegovy and Ozempic, could be manufactured for as little as $3 per month. Researchers estimate production costs between $28 and $140 annually, suggesting significant potential for increased access in low- and middle-income countries as patents begin to expire in key markets like India and Brazil.